Vanda Pharmaceuticals Inc. Forecast, price target & analysts
Vanda Pharmaceuticals Inc. Target price 2026 - Analyst rating & recommendation
Vanda Pharmaceuticals Inc. Classifications & Recommendation
Vanda Pharmaceuticals Inc. Price Target
| Target Price | $11.73 |
| Price | $5.03 |
| Potential |
133.20%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Vanda Pharmaceuticals Inc. 2027 .
The average Vanda Pharmaceuticals Inc. target price is $11.73.
This is
133.20%
register free of charge
$21.00
317.50%
register free of charge
$5.81
15.46%
register free of charge
|
|
| A rating was issued by 10 analysts: 8 Analysts recommend Vanda Pharmaceuticals Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Vanda Pharmaceuticals Inc. stock has an average upside potential 2027 of
133.20%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 216.11 | 253.53 |
| 8.72% | 17.32% | |
| EBITDA Margin | -66.71% | 4.79% |
| 297.10% | 107.18% | |
| Net Margin | -102.02% | -73.01% |
| 972.91% | 28.43% |
6 Analysts have issued a sales forecast Vanda Pharmaceuticals Inc. 2026 . The average Vanda Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Vanda Pharmaceuticals Inc. EBITDA forecast 2026. The average Vanda Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2025 | $-144m | 331.75% |
|---|---|---|
| 2026 |
$12.1m
108.42%
unlock
|
|
EBITDA Margin
| 2025 | -66.71% | 297.10% |
|---|---|---|
| 2026 |
4.79%
107.18%
unlock
|
|
6 Vanda Pharmaceuticals Inc. Analysts have issued a net profit forecast 2026. The average Vanda Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.74 | -3.08 |
| 1,033.33% | 17.65% | |
| P/E | negative | |
| EV/Sales | 0.42 |
6 Analysts have issued a Vanda Pharmaceuticals Inc. forecast for earnings per share. The average Vanda Pharmaceuticals Inc. EPS is
This results in the following potential growth metrics and future valuations:
Vanda Pharmaceuticals Inc....
Current Vanda Pharmaceuticals Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | Sep 23 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 11 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Mar 05 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 23 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 05 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Sep 23 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 11 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Mar 05 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 23 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 05 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
